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A novel colorimetric assay for a-methylacyl-CoA
racemase 1A (AMACR; P504S) utilizing the
elimination of 2,4-dinitrophenolate†
Maksims Yevglevskis,a Guat L. Lee,a Amit Nathubhai,a Yoana D. Petrova,a
Tony D. James, b Michael D. Threadgill,a Timothy J. Woodmana and
Matthew D. Lloyd *a
a-Methylacyl-CoA racemase (AMACR; P504S) regulates branched-
chain fatty acid degradation, activates Ibuprofen and is a recognised
cancer drug target. A novel, facile colorimetric assay was developed
based on elimination of 2,4-dinitrophenolate. The assay was used to
test 5 known inhibitors, determining IC50 and Ki values, reversibility
and characterizing irreversible inhibition.
a-Methylacyl-CoA racemase (AMACR;‡ P504S; E.C. 5.1.99.4) per-
forms a key role in branched-chain fatty acid b-oxidation and the
pharmacological activation of Ibuprofen and related drugs.1,2
AMACR catalyses its reaction by a deprotonation/reprotonation
mechanism,3–5 in which either epimer of a 2-methylacyl-CoA or
2-arylpropanoyl-CoA substrate is converted to a near 1 :1 mixture of
epimers.3,5 Conversion of R-2-methylacyl-CoAs to their S-epimers
enables degradation by b-oxidation.1,6 R-Ibuprofen and most related
R-2-APA drugs1 are pharmacologically activated by conversion to
their corresponding acyl-CoA esters, before epimerization by
AMACR. Hydrolysis of the epimeric products gives a mixture of
R- and S-2-APA drugs, with the R-product recycled by the same
pathway. Thus, inactive R-2-APA drugs are converted into their
S-enantiomers, which are potent inhibitors of cyclooxygenase.7
Concentrations of AMACR are increased in all prostate
cancers,8,9 and in several other cancers.10–13 Increased AMACR
catalytic activity has also been reported in prostate cancer.14,15
Reducing the cellular AMACR 1A15–17 protein using siRNA or
shRNA reduces proliferation of prostate cancer cell lines via
a pathway which is synergistic with androgen withdrawal.15
Some advanced prostate cancer cell lines revert from androgen-
independent to androgen-dependent status17 upon AMACR knock-
down. Consequently, AMACR has attracted considerable interest
as a novel prostate cancer drug target16,18–20 and biomarker.1,21
Despite this interest, few inhibitors of AMACR have been
reported. The majority of inhibitors are rationally designed acyl-
CoA derivatives,18–20,22 which do not comply with Lipinski’s
guidelines23 and need to be delivered as carboxylate prodrugs.
Drug delivery can be limited by in vivo conversion of the prodrug to
the acyl-CoA drug, although preliminary in vivo studies24 appear
promising. N-Dodecyl-N-methylcarbamoyl-CoA 1, a transition-state
analogue, is the most potent inhibitor reported to date.19 Several
non-specific protein-modifying agents also inhibit AMACR.16 No
structure–activity relationships have been reported, probably due
to the difficulties in assaying enzyme activity.
AMACR catalyses the conversion of either R- or S-2-methylacyl-
CoA esters into a near 1 : 1 mixture of epimers3,5 (Scheme 1A).
Assaying AMACR activity is challenging due to the reversibility of
the reaction and the difficulties in differentiating the epimeric
products since the stereochemical centre undergoing a change in
configuration is remote from the stereochemical centres in the CoA
moiety. Several endpoint assays have been reported and used for
inhibitor testing, such as those using chiral acyl-CoA substrates18,19
or their derivatives.25 Notably, Wilson et al.16 reported screening
Scheme 1 Reactions catalysed by AMACR. (A) Conversion of R- or S-2-
methylacyl-CoA into an epimeric mixture, as illustrated by ibuprofenoyl-
CoA 2. Assays commonly use an acyl-CoA substrate with a-3H which is
‘washed out’,16 or unlabelled substrate in the presence of 2H2O followed
by 1H NMR analysis of the ‘washed in’ product.3,5 (B) The elimination of HF
from (2R,3R)-3-fluoro-2-methyldecanoyl-CoA 3 to give unsaturated pro-
duct 4.
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of a library of 5000 compounds using a modified radiolabelled
assay, and identified several non-specific protein modifying
agents that were potent inhibitors of AMACR. Their assay was
used for kinetic analysis of AMACR, but it is an endpoint assay
measuring substrate conversion at a single time-point and
extensive manipulation of samples is required. In addition
the assay is likely to be complicated by the presence of a kinetic
isotope effect. A continuous circular dichroism (CD) assay for
the closely related Mycobacterium tuberculosis enzyme (MCR),
which follows the conversion of either R- or S-ibuprofenoyl-CoA
2 to a near racemic mixture,26 has been used for limited testing
of inhibitors.22 This assay is not subject to a kinetic isotope
effect, but is low-throughput as only one sample can be analysed
at the same time.
It has also been discovered that AMACR catalyses the elimina-
tion of fluoride from substrates such as 3-fluoro-2-methyldecanoyl-
CoA (Scheme 1B), probably via an E1cbmechanism.27 This reaction
has the advantage of being irreversible, and the methyl peaks of
substrate and product do not overlap in the 1H spectrum
allowing a simple route to determine the extent of conversion.
This reaction has been used for the preliminary characterization
of known inhibitors.28
The elimination of fluoride from 3-fluoro-2-methyldecanoyl-
CoA led us to consider whether a colorimetric leaving group
might eliminate from a suitable substrate. The pKa of HF (3.2)
29
and 2,4-dinitrophenol (3.93)30 are similar, suggesting the con-
jugate bases will have similar leaving-group ability. Significantly,
2,4-dinitrophenolate 5 is a well-characterized chromophore
(e354 = 15300 M
1 cm1).31 AMACR is known to accept substrates
with a wide variety of side-chain structures,1 and hence the use of
a substrate containing a 2,4-dinitrophenoxy- moiety as a chromo-
genic leaving group was investigated.
Racemic 3-(2,4-dinitrophenoxy)-2-methylpropanoyl-CoA 6 was
synthesized (Scheme 2) by reaction of Sanger’s reagent 7 with
2-methylpropan-1,3-diol 8 under basic conditions. Treatment
of alcohol 9 with CrO3 and H2SO4 resulted in the racemic
acid 10. This was coupled with CoA–SH5,27,28 to give the desired
substrate 6.
Incubation of 6 with active AMACR resulted in an elimination
reaction (Scheme 3A). The sample containing active enzyme
possessed an intense yellow colour, which was absent from
negative controls (Scheme 3B). 1H NMR analysis confirmed that
2,4-dinitrophenolate 5 and the predicted unsaturated product 11
were formed (Scheme 3C). Incubation of substrate 6 with active
enzyme in amicrotitre plate led to a rapid increase in absorbance
at 354 nm, which was not observed in controls containing heat-
inactivated enzyme (Scheme 3D). This reaction occurred in an
enzyme concentration-dependent manner (ESI,† Fig. S1 and S2).
Assay conditions were optimized (ESI,† Fig. S3–S5) by inves-
tigating the effect of various additives on enzymatic activity.
Addition of 2-mercaptoethanol, dithiothreitol or BSA had no
significant effect on activity. Addition of 0.1% (v/v) Triton X-100 to
the assay mixture resulted in a modest reduction of activity. This
is probably due to the formation of micelles, as the amounts used
are above the reported critical micellar concentrations for Triton
X-100 (0.19 and 1.25 mM).32 In contrast, addition of 1.5% (w/v)
N-lauroyl-sarcosine reduced activity to levels observed in negative
controls. The enzyme proved to be tolerant of DMSO (ESI,†
Fig. S5), up to at least 8% (v/v) (B1.12 M). Michaelis–Menten
kinetic behaviour was observed under the optimized assay conditions
(ESI,† Fig. S6) and the following kinetic parameters were determined:
Km = 58 mM; Vmax = 112 nmol min
1 mg1; kcat = 0.088 s
1; kcat/Km =
1517 M1 s1. Optimised conditions for the assay were B8 mg
enzyme in 200 mL NaH2PO4–NaOH aq., pH 7.4 containing
40 mM 6 and up to 8% (v/v) DMSO at 30 1C, monitoring at
354 nm. Typical rates for active enzyme and negative controls
Scheme 2 Synthesis of substrate 6. Reagents & conditions: (i) Na metal,
83%; (ii) CrO3, conc. H2SO4, acetone, 67%; (iii) carbonyldiimidazole,
CH2Cl2; (iv) CoA–SH (Li
+)3, 0.1 M NaHCO3aq./THF (1 : 1).
Scheme 3 Elimination of 2,4-dinitrophenolate 5 from 3-(2,4-dinitrophenoxy)-
2-methylpropanoyl-CoA 6 by AMACR. (A) Reaction catalysed by enzyme;
(B) NMR tubes showing samples containing active enzyme (yellow) and
heat-inactivated enzyme (clear); (C) 1H NMR spectra (500 MHz) of samples
in B showing position of methyl groups of substrate 6 (red circles)
and product 11 (green circles); (D) time course of reaction followed
by monitoring absorbance of 2,4-nitrophenoxide 5 at 354 nm, showing
negative control (heat-inactivated enzyme; red) and active enzyme (green).
Assays comprised 40 mM 6 and recombinant AMACR (9.25 mg) in 100 mL
NaH2PO4–NaOH, pH 7.4. Data are means  SDM (n = 3).
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(means SD, n = 3) are 33 1.9 and 0.72 0.24 nmolmin1mg1.
The limit of detection is B1.4 nmol min1 mg1. The dynamic
range is B1.4–255 nmol min1 mg1. The sensitivity threshold is
B0.5–1.0 nmol min1 mg1. The Z0* value33 for the assay was 0.906
(see ESI,† for further details on how these values were calculated).
The presence of other enzymes such as branched-chain acyl-CoA
oxidases (ACOXs) could potentially generate a false positive signal,
but this can be avoided by using R-6 as ACOXs are known to be
specific for S-2-methylacyl-CoA substrates.6
This new colorimetric assay for AMACR was validated using
a series of known inhibitors for which bench-mark values
are available (Fig. 1). N-Dodecyl-N-methylcarbamoyl-CoA 1 and
ibuprofenoyl-CoA 2 were chosen as representative acyl-CoA
inhibitors. Ebselen 12, Ebselen Oxide 13 and Rose Bengal 14
were chosen as examples of the non-specific protein modifying
agents reported by Wilson et al.16 Inhibitor potency was initially
assessed using dose–response curves to determine IC50 values
(see Fig. 1B and C for example).
N-Dodecyl-N-methylcarbamoyl-CoA 1 had a very low IC50
value of 0.4 nM determined by this assay, confirming its very
high potency. This compares with the previous value of 98 nM,
determined with an endpoint assay.19 Ibuprofenoyl-CoA 2 had a
modest potency with an IC50 value of 554 nM. For both inhibitors
activity was restored upon rapid dilution of the inhibitor, showing
reversible inhibition. Michaelis–Menten kinetic analysis of com-
pounds 1 and 2 showed that they were both competitive inhibitors
of AMACR, with Ki values of 0.65 and 60 nM, respectively (Fig. 2
and ESI,† Fig. S7 and S8). It is noteworthy that both compounds
appear to be much more potent when assayed using this method
compared with other methods. Ki values of 98 nM and 56 mM
were previously reported in the literature for N-dodecyl-N-
methylcarbamoyl-CoA 119 and racemic ibuprofenoyl-CoA 234
(with native rat enzyme), respectively. The reasons for the
difference in apparent potency are not clear, but it probably
results from differences in assay conditions including micelle
formation by acyl-CoA substrates and inhibitors.
Analysis of the non-specific protein modification agents 12, 13
and 14, identified byWilson et al.16 as AMACR inhibitors, confirmed
their potency. Ebselen 12 gave an IC50 value of 133 nM, compared to
the previously reported value16 of 2.789 mM. Rapid dilution of
Ebselen 12 resulted in part restoration of activity in our assay (ESI,†
Fig. S7), consistent with irreversible inhibition. This is consistent
with the complex behaviour observed by Wilson et al.16
Similarly, Ebselen Oxide 13 was a potent inhibitor with an IC50
value of 774 nM compared to the previously reported value16 of
795 nM. Rapid dilution of 13 did not result in full restoration of
activity, suggesting (covalent) irreversible inhibition. Further
investigation showed that non-saturating time-dependent inhibi-
tion of AMACR occurred, with a second-order rate constant of
116  8 M1 s1 (Fig. 3 and ESI,† Fig. S10), consistent with 13
being a non-specific inhibitor operating by a one-step mechanism.
Compound 14 was a reversible inhibitor (IC50 = 3259 nM),
compared to 10000 nM.16 Prolonged incubation caused photolytic
protein degradation (ESI,† Fig. S9).
AMACR has attracted much attention as both a novel drug
target and cancer biomarker since the first reports of its involve-
ment in prostate cancer in 2003.15 Exploitation of this discovery
has been very limited due to the absence of a suitable assay.
Our novel colorimetric assay provides a versatile platform for
detailed characterization of inhibitors and determination of
Fig. 1 Inhibitors used in assay. (A) Chemical structures and determined IC50
values from dose–response curves; (B) example assay in 96-well plate. The
pink colour results from the presence of the inhibitor Rose Bengal 14 and
the yellow colour from the 2,4-dinitrophenolate 5 produced by the enzyme
from substrate 6; (C) dose–response curve for Rose Bengal 14.
Fig. 2 Analysis of inhibitor 1. (A) Reversibility experiment, showing enzymatic
activity is restored upon dilution of concentrated enzyme with 13.5 nM 1 to
0.27 nM 1; (B) kinetic analysis to determine Ki value for 1.
Fig. 3 Inactivation of AMACR by Ebselen Oxide 13. (A) Time-dependent
inactivation of recombinant AMACR by Ebselen Oxide 13. Concentrations
of Ebselen Oxide 13 (inset) are given for the pre-incubation phase before
dilution of the enzyme with substrate 6 in the assay; (B) dependence of
inhibition on Ebselen Oxide 13 concentration. First order rate constants
(s1) derived from A was plotted vs. Ebselen Oxide 13 concentration in the
pre-incubation phase. Data are mean  standard error.
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structure–activity relationships. The assay also allows for inter-
rogation of the complex biology of AMACR and its role in lipid
metabolism and cancer. Similar colorimetric assays could
potentially be adapted for use with other enzymes catalysing
reactions via enolate intermediates, including other racemases,35
acyl-CoA oxidases36,37 and other enzymes,38,39 several of which are
of academic, medicinal, or biotechnological interest.
This work was funded by Prostate Cancer UK (S10-03 and
PG14-009), a University of Bath Overseas Research Studentship,
and a Biochemical Society Summer Vacation studentship (2015).
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